Q2 revenue rises 30.8%; 2030 revenue target is twice FY26
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts more than Nifty Smallcap 250 and 1.1 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Poly Medicure reported Q2 FY27 consolidated revenue of Rs 580.5 crore, up 30.8%, and operating profit before depreciation and amortisation of Rs 139.1 crore at a 24.0% margin. H1 revenue rose 30.6% to Rs 1,105.9 crore. Management targets revenue at 2 times the FY26 level by 2030, backed by more research spending, two new plants and wider global sales.
Positive: strong Q2 growth and a quantified 2030 revenue goal may lift sentiment, but execution and integrating recent acquisitions remain risks.